信达生物：双抗双毒素ADC新药获批临床

求实药社01-29

来源：药研网1月29日，CDE官网公示，信达生物一类新药IBI3028的临床试验申请获得批准，用于标准治疗失败的局部晚期、不可切除或转移性实体瘤。据公开资料显示，IBI3028是一款双抗双毒素抗体偶联药物（bispecific dual-payload ADC）。IBI3028基于信达生物自主研发的DuettX 双载荷 ADC 平台构建，创新性地将双特异性抗体与两种作用机制不同的细胞毒性载荷相结合...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2607704071?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-29 12:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2607704071","market":"hk","top_or_hot":-1,"title":"信达生物：双抗双毒素ADC新药获批临床","media":"求实药社","content":"<div>\n<p>来源：药研网1月29日，CDE官网公示，信达生物一类新药IBI3028的临床试验申请获得批准，用于标准治疗失败的局部晚期、不可切除或转移性实体瘤。据公开资料显示，IBI3028是一款双抗双毒素抗体偶联药物（bispecific dual-payload ADC）。IBI3028基于信达生物自主研发的DuettX 双载荷 ADC 平台构建，创新性地将双特异性抗体与两种作用机制不同的细胞毒性载荷相结合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129124216953ed9f4&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>信达生物：双抗双毒素ADC新药获批临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n信达生物：双抗双毒素ADC新药获批临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-29 12:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129124216953ed9f4&s=b><strong>求实药社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>来源：药研网1月29日，CDE官网公示，信达生物一类新药IBI3028的临床试验申请获得批准，用于标准治疗失败的局部晚期、不可切除或转移性实体瘤。据公开资料显示，IBI3028是一款双抗双毒素抗体偶联药物（bispecific dual-payload ADC）。IBI3028基于信达生物自主研发的DuettX 双载荷 ADC 平台构建，创新性地将双特异性抗体与两种作用机制不同的细胞毒性载荷相结合...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129124216953ed9f4&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129124216953ed9f4&s=b","article_id":"2607704071","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129124216953ed9f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607704071","pubTimestamp":1769659279,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"来源：药研网1月29日，CDE官网公示，信达生物一类新药IBI3028的临床试验申请获得批准，用于标准治疗失败的局部晚期、不可切除或转移性实体瘤。据公开资料显示，IBI3028是一款双抗双毒素抗体偶联药物。IBI3028基于信达生物自主研发的DuettX 双载荷 ADC 平台构建，创新性地将双特异性抗体与两种作用机制不同的细胞毒性载荷相结合。目前，IBI3028的具体靶点组合及毒素类型尚未完全披露。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01801":"信达生物","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","BK1583":"高瓴概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1589":"北水核心资产","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1161":"生物科技","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC"},"translate_title":"Innovent: Double-antibody and double-toxin ADC new drug approved for clinical purposes","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1.5},"content_text":"来源：药研网1月29日，CDE官网公示，信达生物一类新药IBI3028的临床试验申请获得批准，用于标准治疗失败的局部晚期、不可切除或转移性实体瘤。据公开资料显示，IBI3028是一款双抗双毒素抗体偶联药物（bispecific dual-payload ADC）。IBI3028基于信达生物自主研发的DuettX 双载荷 ADC 平台构建，创新性地将双特异性抗体与两种作用机制不同的细胞毒性载荷相结合。该设计旨在通过同时识别并靶向两个肿瘤相关抗原，实现对肿瘤细胞的更高选择性富集，并在肿瘤细胞内释放具有互补作用机制的毒素，从而产生协同杀伤效应，有望克服肿瘤异质性及获得性耐药等治疗难题。目前，IBI3028的具体靶点组合及毒素类型尚未完全披露。尽管如此，其临床研究的正式启动，标志着双抗双毒素 ADC 技术路线在肿瘤治疗领域的重要进展，也为难治性实体瘤提供了一种具有潜力的全新治疗策略。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607704071","isCrawlerRequest":true}